Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: A randomized controlled phase 2 trial

OBJECTIVES: In 2017, the World Health Organisation (WHO) pre-qualified a single-dose typhoid conjugate vaccine (TCV) and identified TCV co-administration studies as a research priority. Accordingly, we tested co-administration of Typbar TCV® (Bharat Biotech International) with measles-rubella (MR) a...

Descripción completa

Detalles Bibliográficos
Autores principales: Sirima, Sodiomon B., Ouedraogo, Alphonse, Barry, Nouhoun, Siribie, Mohamadou, Tiono, Alfred, Nébié, Issa, Konaté, Amadou, Berges, Gloria Damoaliga, Diarra, Amidou, Ouedraogo, Moussa, Bougouma, Edith C., Soulama, Issiaka, Hema, Alimatou, Datta, Shrimati, Liang, Yuanyuan, Rotrosen, Elizabeth T., Tracy, J. Kathleen, Jamka, Leslie P., Oshinsky, Jennifer J., Pasetti, Marcela F., Neuzil, Kathleen M., Laurens, Matthew B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8298254/
https://www.ncbi.nlm.nih.gov/pubmed/34082090
http://dx.doi.org/10.1016/j.ijid.2021.05.061

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8298254/
https://www.ncbi.nlm.nih.gov/pubmed/34082090
http://dx.doi.org/10.1016/j.ijid.2021.05.061

Ejemplares similares